Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Ascletis Pharma stock price, quote, forecast and news

1672.HK
KYG0520K1094
A2JRKN

Price

0.88
Today +/-
-0.00
Today %
-3.24 %
P

Ascletis Pharma stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Ascletis Pharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Ascletis Pharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Ascletis Pharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Ascletis Pharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Ascletis Pharma Stock Price History

DateAscletis Pharma Price
9/5/20240.88 undefined
9/4/20240.91 undefined
9/3/20240.89 undefined
9/2/20240.85 undefined
8/30/20240.77 undefined
8/29/20240.76 undefined
8/28/20240.72 undefined
8/27/20240.72 undefined
8/26/20240.72 undefined
8/23/20240.71 undefined
8/22/20240.74 undefined
8/21/20240.75 undefined
8/20/20240.74 undefined
8/19/20240.73 undefined
8/16/20240.76 undefined
8/15/20240.76 undefined
8/14/20240.74 undefined
8/13/20240.75 undefined
8/12/20240.78 undefined
8/9/20240.81 undefined

Ascletis Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Ascletis Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Ascletis Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Ascletis Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Ascletis Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Ascletis Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Ascletis Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Ascletis Pharma’s growth potential.

Ascletis Pharma Revenue, EBIT and net profit per share

DateAscletis Pharma RevenueAscletis Pharma EBITAscletis Pharma Net Income
2026e45.03 M undefined-314.91 M undefined-340.81 M undefined
2025e0 undefined-327.15 M undefined-295.71 M undefined
2024e0 undefined-315.58 M undefined-220.53 M undefined
202356.6 M undefined-302.25 M undefined-144.72 M undefined
202254.09 M undefined-399.46 M undefined-314.84 M undefined
202176.9 M undefined-206 M undefined-199 M undefined
202035 M undefined-236.3 M undefined-209.2 M undefined
2019173.4 M undefined-159.6 M undefined-96 M undefined
2018166.3 M undefined-70.3 M undefined-7.3 M undefined
201753.2 M undefined-67.5 M undefined-53.9 M undefined
201633 M undefined-44.3 M undefined-26.8 M undefined

Ascletis Pharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (B)DOCUMENTS
201620172018201920202021202220232024e2025e2026e
3353166173357654560045
-60.61213.214.22-79.77117.14-28.953.70---
100.00100.0092.1771.68-65.7151.32-44.4444.64---
3353153124-2339-2425000
-44-67-70-159-236-206-399-302-315-327-314
-133.33-126.42-42.17-91.91-674.29-271.05-738.89-539.29---697.78
-26-53-7-96-209-199-314-144-220-295-340
-103.85-86.791,271.43117.71-4.7857.79-54.1452.7834.0915.25
1.121.120.871.051.041.11.091.07000
-----------
Details

Keystats

ⓘ

Revenue and Growth

The Ascletis Pharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Ascletis Pharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (k)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
20162017201820192020202120222023
               
0.420.753.172.992.712.52.482.3
006887.328.553.623.875.43
0019.919.121.916.45.414.28
18.762.283.98658.956.220.526.07
22.762.218.4116.74.612.97.57
0.470.883.363.192.832.632.542.33
49.879.188.698.784.677.973.0468.54
00058.160.941.922.0263.02
0000005.40
20.436.575.475.690.778.216.5626.32
00000000
000.31.40.90.40.70.38
70.2115.6164.3233.8237.1198.4117.72158.25
0.540.993.533.433.072.832.662.49
               
00800800800700742731
0.090.092.962.912.92.882.872.84
161.8489.6439.2346.3141.7-50.2-362.79-509.48
18.315.228.164-54.3-86.335.1159.63
00000000
0.270.63.433.322.992.752.542.39
01314.26.60.91.13.140.65
0032.437.731.148.354.690.15
73.486.346.84140.64048.0444.17
00000000
0002.21.11.62.425.71
73.499.393.487.573.791108.19140.68
0001.60.41.21.822.71
0100000000
53.822.16.812.911.28.77.155.56
53.822.26.814.511.69.98.978.26
127.2121.5100.210285.3100.9117.16148.94
0.40.723.533.433.072.852.662.54
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Ascletis Pharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Ascletis Pharma's financial health and stability.

Assets

Ascletis Pharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Ascletis Pharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Ascletis Pharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Ascletis Pharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2016201720182019202020212022
-31-80-19-95-209-199-314
251122272930
0000000
17-106-6655681459
0-17-22-5529882
0000000
0700000
-12-198-96-74-84-146-142
-44-35-60-28-38-7-14
-37-644-817602132-274-1,297
6-608-757630171-267-1,282
0000000
000-1-2-2-2
-0.2402.97-0.05-0.02-0.030
0.090.552.56-0.05-0.02-0.03-0
330549-3520000
00-570000
0.05-0.31.660.51-0.08-0.48-1.32
-57.11-234.01-156.67-102.57-123.87-154.13-156.85
0000000

Ascletis Pharma stock margins

The Ascletis Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ascletis Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ascletis Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Ascletis Pharma's sales revenue. A higher gross margin percentage indicates that the Ascletis Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Ascletis Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Ascletis Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Ascletis Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Ascletis Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Ascletis Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Ascletis Pharma Margin History

Ascletis Pharma Gross marginAscletis Pharma Profit marginAscletis Pharma EBIT marginAscletis Pharma Profit margin
2026e45.92 %-699.36 %-756.9 %
2025e45.92 %0 %0 %
2024e45.92 %0 %0 %
202345.92 %-534.04 %-255.7 %
2022-45.65 %-738.51 %-582.07 %
202150.98 %-267.88 %-258.78 %
2020-67.14 %-675.14 %-597.71 %
201971.68 %-92.04 %-55.36 %
201892.54 %-42.27 %-4.39 %
2017100 %-126.88 %-101.32 %
2016100 %-134.24 %-81.21 %

Ascletis Pharma Stock Sales Revenue, EBIT, Earnings per Share

The Ascletis Pharma earnings per share therefore indicates how much revenue Ascletis Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ascletis Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ascletis Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ascletis Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ascletis Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Ascletis Pharma Revenue, EBIT and net profit per share

DateAscletis Pharma Sales per ShareAscletis Pharma EBIT per shareAscletis Pharma Earnings per Share
2026e0.05 undefined0 undefined-0.35 undefined
2025e0 undefined0 undefined-0.3 undefined
2024e0 undefined0 undefined-0.22 undefined
20230.05 undefined-0.28 undefined-0.13 undefined
20220.05 undefined-0.37 undefined-0.29 undefined
20210.07 undefined-0.19 undefined-0.18 undefined
20200.03 undefined-0.23 undefined-0.2 undefined
20190.16 undefined-0.15 undefined-0.09 undefined
20180.19 undefined-0.08 undefined-0.01 undefined
20170.05 undefined-0.06 undefined-0.05 undefined
20160.03 undefined-0.04 undefined-0.02 undefined

Ascletis Pharma business model

Ascletis Pharma Inc is a bio-pharmaceutical company that was founded in Hong Kong in 2009. The focus of the company is the development and marketing of drugs for the treatment of infectious diseases and cancer. The business model of Ascletis Pharma Inc is based on research and development, as well as sales and marketing activities. The company collaborates closely with academic institutions and clinical researchers to discover and develop new drugs. In recent years, Ascletis has received various awards and recognitions for its products. The company's portfolio includes various areas, such as the treatment of viral infectious diseases like hepatitis B and C infections. They have also developed drugs for the treatment of solid tumors, such as gastric cancer and liver cancer. Alongside medical research, Ascletis also conducts various sales and marketing activities. The company works with partners to market its products worldwide. In summary, Ascletis Pharma Inc is an emerging bio-pharmaceutical company specializing in the development of drugs for the treatment of infectious diseases and cancer. The business model is based on research and development, as well as sales and marketing of products. The company has various divisions and offers a variety of products. Ascletis has experienced continuous growth in recent years and is considered one of the most innovative companies in the industry. Ascletis Pharma is one of the most popular companies on Eulerpool.com.

Ascletis Pharma SWOT Analysis

Strengths

Ascletis Pharma Inc has a strong and experienced management team that possesses deep knowledge and expertise in the pharmaceutical industry. This allows them to make informed decisions and navigate the complex regulatory environment effectively.

The company has a diverse pipeline of innovative and high-quality products. This enables Ascletis Pharma Inc to expand its product portfolio and cater to a wide range of therapeutic areas, thereby reducing dependence on a single drug or market.

Weaknesses

Ascletis Pharma Inc may face challenges in terms of limited financial resources compared to larger pharmaceutical companies. This could potentially hinder their ability to invest in research and development, marketing, and expanding manufacturing capabilities.

The company might also face difficulties in protecting its intellectual property rights. As the pharmaceutical market is highly competitive, there is a risk of imitation or infringement by competitors, which can impact Ascletis Pharma Inc's market share and profitability.

Opportunities

Ascletis Pharma Inc can leverage the growing demand for innovative and effective treatments in emerging markets. Expanding into these markets can drive revenue growth and diversify the customer base.

Additionally, collaborations and partnerships with other pharmaceutical companies or research institutions can provide opportunities for knowledge sharing, access to new technologies, and joint product development, enabling Ascletis Pharma Inc to advance its pipeline and expand its market reach.

Threats

Ascletis Pharma Inc faces the risk of increased competition from both established pharmaceutical companies and emerging players. This can impact pricing power, market share, and overall profitability.

Regulatory challenges and changes in government policies can also pose a threat to Ascletis Pharma Inc's operations. Strict regulations or delays in regulatory approvals of new products can significantly affect timelines, product launches, and revenue generation.

Ascletis Pharma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Ascletis Pharma historical P/E ratio, EBIT, and P/S ratio.

Ascletis Pharma shares outstanding

The number of shares was Ascletis Pharma in 2023 — This indicates how many shares 1.074 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ascletis Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ascletis Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ascletis Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ascletis Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Ascletis Pharma.

Ascletis Pharma list of shareholders

%
Name
Stocks
Change
Date
8.55 % Wu (Hejingdao Judy)83,982,9141,155,5001/12/2024
6.38 % JJW11 Ltd62,689,872-819,9491/4/2024
52.46 % Wu (Jinzi Jason)515,549,164-1,155,5001/12/2024
5.16 % CBC Investment Twelve Ltd50,729,518012/31/2022
1.37 % CBC Investment Fifteen Ltd13,425,209012/31/2022
0.80 % E Fund Management Co. Ltd.7,888,000012/31/2023
0.46 % JPMorgan Asset Management (China) Company Limited.4,475,0002,379,0006/30/2023
0.36 % Dimensional Fund Advisors, L.P.3,539,000318,0001/31/2024
0.18 % China Universal Asset Management Co., Ltd.1,818,000840,0006/30/2023
0.18 % Fullgoal Fund Management Co., Ltd.1,725,000-2,286,00012/31/2023
1
2
3
4

Ascletis Pharma Executives and Management Board

Dr. Jinzi Jason Wu59
Ascletis Pharma Executive Chairman of the Board, Chief Executive Officer (since 2013)
Compensation 19.94 M
Mrs. Judy Hejingdao Wu48
Ascletis Pharma Senior Vice President, Executive Director (since 2014)
Compensation 2.5 M
Mr. Jiong Gu50
Ascletis Pharma Non-Executive Independent Director
Compensation 369,000
Ms. Lin Hua48
Ascletis Pharma Non-Executive Independent Director
Compensation 369,000
Dr. Yizhen Wei47
Ascletis Pharma Non-Executive Independent Director
Compensation 369,000
1
2

Most common questions regarding Ascletis Pharma

What values and corporate philosophy does Ascletis Pharma represent?

Ascletis Pharma Inc is a renowned pharmaceutical company committed to delivering innovative and high-quality healthcare solutions. The company's core values encompass integrity, collaboration, and patient-centricity. Ascletis Pharma Inc strives to make a positive impact on society by providing breakthrough therapies and improving patient outcomes. With a focus on research and development, Ascletis Pharma Inc aims to address unmet medical needs and bring cutting-edge treatments to individuals worldwide. By upholding these values and embracing a patient-first approach, Ascletis Pharma Inc establishes itself as a trusted leader in the pharmaceutical industry.

In which countries and regions is Ascletis Pharma primarily present?

Ascletis Pharma Inc is primarily present in China. The company is headquartered in Hangzhou, Zhejiang Province, China. Ascletis Pharma Inc is a leading innovative biotechnology company focused on the research, development, and commercialization of innovative therapies for the treatment of liver diseases and viral infections, with a particular emphasis on hepatitis B. With a strong presence in China, Ascletis Pharma Inc is dedicated to improving patient outcomes and addressing the unmet medical needs in the region.

What significant milestones has the company Ascletis Pharma achieved?

Ascletis Pharma Inc has achieved several significant milestones. The company has successfully developed and received regulatory approval for a range of innovative drugs, including Ganovo, a direct-acting antiviral for the treatment of chronic hepatitis C. Ascletis Pharma Inc has also established a strong partnership network with renowned global pharmaceutical companies and research institutions. Furthermore, the company has expanded its global presence by entering into licensing agreements and collaborations for the commercialization of its products in various markets worldwide. These accomplishments reflect Ascletis Pharma Inc's commitment to advancing healthcare by delivering breakthrough therapies and driving growth in the pharmaceutical industry.

What is the history and background of the company Ascletis Pharma?

Ascletis Pharma Inc is a reputable pharmaceutical company with a rich history and background. Founded in 2011, Ascletis Pharma Inc focuses on developing and commercializing innovative drugs for viral hepatitis and other liver diseases. The company has built a strong presence in the global pharmaceutical market through its dedication to research and development. Ascletis Pharma Inc has established itself as a leader in the field of antiviral therapies, with a diverse portfolio of products and a commitment to improving patient outcomes. With its strong track record and commitment to innovation, Ascletis Pharma Inc continues to make significant contributions to the healthcare industry.

Who are the main competitors of Ascletis Pharma in the market?

The main competitors of Ascletis Pharma Inc in the market are national and multinational pharmaceutical companies that operate in the same therapeutic areas as Ascletis, such as antiviral medications and liver disease treatments. These competitors include Gilead Sciences Inc, AbbVie Inc, Bristol-Myers Squibb Company, and Johnson & Johnson.

In which industries is Ascletis Pharma primarily active?

Ascletis Pharma Inc is primarily active in the pharmaceutical industry.

What is the business model of Ascletis Pharma?

Ascletis Pharma Inc is a biopharmaceutical company specializing in the research, development, and commercialization of innovative drugs for the treatment of liver diseases and cancer. As part of its business model, Ascletis Pharma Inc focuses on identifying and acquiring promising drug candidates, conducting clinical trials to evaluate their efficacy and safety, obtaining necessary regulatory approvals, and eventually commercializing the approved drugs in global markets. Through its commitment to breakthrough research and strategic collaborations, Ascletis Pharma Inc aims to address unmet medical needs and improve patient outcomes.

What is the P/E ratio of Ascletis Pharma 2024?

The Ascletis Pharma P/E ratio is -4.3.

What is the P/S ratio of Ascletis Pharma 2024?

The Ascletis Pharma P/S ratio is 0.

What is the AlleAktien quality score of Ascletis Pharma?

The AlleAktien quality score for Ascletis Pharma is 3/10.

What is the revenue of Ascletis Pharma 2024?

The revenue cannot currently be calculated for Ascletis Pharma.

How high is the profit of Ascletis Pharma 2024?

The expected Ascletis Pharma profit is -220.53 M CNY.

What is the business model of Ascletis Pharma

The company Ascletis Pharma Inc is an innovative biopharmaceutical company based in China, specializing in the development and marketing of drugs for people with serious and life-threatening diseases such as Hepatitis B, Hepatitis C, HIV/AIDS, and solid tumors. They conduct extensive research and development activities in collaboration with their subsidiaries and joint venture partners. Ascletis is a leading provider of self-developed Category 1 medications, with products available in China and other selected markets. Their main areas of focus are research and development, production, and marketing of pharmaceuticals. They strive to invest regularly in new developments, particularly in researching and developing new medicines for treating serious and life-threatening diseases. The company has achieved recent successes in launching new products for patients with serious illnesses, such as innovative medicines for Hepatitis B, Hepatitis C, and HIV/AIDS. In addition to their core business, Ascletis has also ventured into the development of diagnostic products. Their strategy includes establishing a strong presence in the Chinese market and selected regional markets, as well as pursuing international expansion through collaborations and acquisitions. Overall, Ascletis Pharma Inc is an innovative biopharmaceutical company dedicated to the development and marketing of drugs for the treatment of serious and life-threatening diseases such as Hepatitis B, Hepatitis C, HIV/AIDS, and solid tumors. They conduct extensive research and development activities, and possess a strong production and distribution organization. With their unique combination of scientific expertise and operational efficiency, Ascletis is able to develop and implement innovative solutions in various sectors of the healthcare industry.

What is the Ascletis Pharma dividend?

Ascletis Pharma pays a dividend of 0 CNY distributed over payouts per year.

How often does Ascletis Pharma pay dividends?

The dividend cannot currently be calculated for Ascletis Pharma or the company does not pay out a dividend.

What is the Ascletis Pharma ISIN?

The ISIN of Ascletis Pharma is KYG0520K1094.

What is the Ascletis Pharma WKN?

The WKN of Ascletis Pharma is A2JRKN.

What is the Ascletis Pharma ticker?

The ticker of Ascletis Pharma is 1672.HK.

How much dividend does Ascletis Pharma pay?

Over the past 12 months, Ascletis Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ascletis Pharma is expected to pay a dividend of 0 CNY.

What is the dividend yield of Ascletis Pharma?

The current dividend yield of Ascletis Pharma is .

When does Ascletis Pharma pay dividends?

Ascletis Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ascletis Pharma?

Ascletis Pharma paid dividends every year for the past 0 years.

What is the dividend of Ascletis Pharma?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ascletis Pharma located?

Ascletis Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ascletis Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ascletis Pharma from 9/7/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 9/7/2024.

When did Ascletis Pharma pay the last dividend?

The last dividend was paid out on 9/7/2024.

What was the dividend of Ascletis Pharma in the year 2023?

In the year 2023, Ascletis Pharma distributed 0 CNY as dividends.

In which currency does Ascletis Pharma pay out the dividend?

The dividends of Ascletis Pharma are distributed in CNY.

All fundamentals about Ascletis Pharma

Our stock analysis for Ascletis Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ascletis Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.